Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 + ruxolitinib dose-finding study in myelofibrosis
NL-OMON41302Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonidegib and ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities. Started May 2014; status: active, not recruiting.
02
Drugs
sonidegibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON41302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41302.